Advertisement

Breast Cancer Research and Treatment

, Volume 3, Issue 1, pp 91–95 | Cite as

Adjuvant chemotherapy with cyclophosphamide or CMF in premenopausal women with stage II breast cancer

  • H. Brincker
  • H. T. Mouridsen
  • K. W. Andersen
  • statistician, on behalf of the Danish Breast Cancer Cooperative Group (DBCG)
Scandinavian Breast Cancer Symposium

Summary

After total mastectomy and partial axillary dissection, 805 premenopausal women with stage II breast cancer were randomized to receive postoperative radiotherapy (RT) alone, RT + cyclophosphamide (C) for 12 monthly cycles, or RT + cyclophosphamide/methotrexate/5-fluorouracil (CMF) for 12 monthly cycles. At 3 years actuarial relapse-free survival for RT + C and RT + CMF was significantly better than for RT alone (p = 0.0009 and 0.0001, respectively). There was no significant difference in relapse-free survival between RT + C and RT + CMF.

C resulted in more pronounced haematologic toxicity and a higher frequency of amenorrhoea and of alopecia than CMF, while CMF resulted in more pronounced nausea and stomatitis than C.

In the preliminary results, C alone may be as effective as CMF in prolonging relapse-free survival in premenopausal women with stage II breast cancer.

Keywords

adjuvant therapy breast cancer CMF cyclophosphamide 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Biran S, Brufman G, Robinson E, Borovik R, Brenner H, Rath P: Adjuvant radiotherapy with and without chemotherapy for stage II breast cancer: A national randomized study (abstract). Proc Am Soc Clin Oncol 1982, p. 83Google Scholar
  2. 2.
    Fisher B, Redmond C, Wolmark N, Wieand HS: Diseasefree survival at intervals during and following completion of adjuvant chemotherapy. Cancer 48:1271–1280, 1981Google Scholar
  3. 3.
    Howell A, Bush H, Howat J, Bramwell V, Harland RL, Crowther D, Sellwood RA: A controlled trial of adjuvant CMF and melphalan in patients with operable breast cancer (abstract). UICC Conference on Clinical Oncology, Lausanne, Switzerland, October 1981Google Scholar
  4. 4.
    Koyama H, Wada T, Takahashi Y, Nishizawa Y, Iwanaga T, Aoki Y, Teraxawa T, Kosaki G, Kajita A, Wada A: Surgical adjuvant chemotherapy with mitomycin C and cyclophosphamide in Japanese patients with breast cancer. Cancer 46:2373–2379, 1980PubMedGoogle Scholar
  5. 5.
    Nissen-Meyer R: Chemotherapy and endocrine therapy of primary breast cancer. Reviews on Endocrine-Related Cancer, Suppl 6:71–82, 1980Google Scholar
  6. 6.
    Rossi A, Bonadonna G, Tancini G, Bajetta E, Marchini S, Valagussa P, Veronesi U: Trials of adjuvant chemotherapy in breast cancer. The experience of the Istituto Nazionale Tumori of Milan.In HT Mouridsen and T Palshof (eds). Breast Cancer — Experimental and Clinical Aspects. Pergamon Press, Oxford, 1980, pp 149–156Google Scholar
  7. 7.
    Senn HJ, Amgwerd R, Junge WF: Adjuvant chemo (immuno) therapy with LMF + BCG in node-negative and node-positive breast cancer. 5-year results of a randomized study. Proc Am Soc Clin Oncol 22:426, 1981Google Scholar
  8. 8.
    Ahmann DL, Scanlon PW, Bisel HF, Edmonson HJ, Frytak S, Payne WS, O'Fallon JR, Hahn RJ, Ingle JN, O'Connel MJ, Rubin J: Repeated adjuvant chemotherapy with phenylalanine mustard, or 5-fluorouracil, cyclophosphamide and prednisone with or without radiation after mastectomy for breast cancer. Lancet 1:893–896, 1978PubMedGoogle Scholar
  9. 9.
    Glucksberg H, Rivkin S, Rasmussen S: Adjuvant chemotherapy for operable breast cancer with positive axillary nodes (abstract). Proc Am Soc Clin Oncol 22:426, 1981Google Scholar
  10. 10.
    Andersen KW, Mouridsen HT, Castberg T, Fischerman K, Andersen J, Hou-Jensen K, Brincker H, Johansen H, Henriksen E, Rørth M, Rossing N: Organisation of the Danish adjuvant trials in breast cancer. Dan Med Bull 28:102–106, 1981PubMedGoogle Scholar
  11. 11.
    Bonadonna G, Valagussa P: Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 304:10–15, 1981PubMedGoogle Scholar
  12. 12.
    Lee Y-TN, Sakulsky SB: Adjuvant chemotherapy (CMF) for breast carcinoma: Patient's compliance and total dose achieved (abstract). Proc Am Soc Clin Oncol 22:432, 1981Google Scholar
  13. 13.
    Glucksberg H, Rivkin SE, Rasmussen S: Adjuvant chemotherapy for stage II breast cancer: A comparison of CMFVP versus L-PAM.In SE Jones and SE Salmon (eds). Adjuvant Therapy of Cancer II. Grune and Stratton, New York, 1979, pp 261–268Google Scholar
  14. 14.
    Tancini G, Bajetta E, Marchini S, Valagussa P, Bonadonna G, Veronesi U: Preliminary 3-year results of 12 versus 6 cycles of surgical adjuvant CMF in premenopausal breast cancer. Cancer Clin Trials 2:285–292, 1979PubMedGoogle Scholar
  15. 15.
    Velez-Garcia E, Moore M, Marcial V, Bartolucci A, Ketcham A, Smalley R: Adjuvant chemotherapy and radiotherapy in stage II breast cancer (abstract). Proc Am Soc Clin Oncol 1982, p 80Google Scholar

Copyright information

© Martinus Nijhoff Publishers 1983

Authors and Affiliations

  • H. Brincker
    • 1
  • H. T. Mouridsen
    • 2
  • K. W. Andersen
    • 2
  • statistician, on behalf of the Danish Breast Cancer Cooperative Group (DBCG)
  1. 1.Department of Oncology and RadiotherapyOdense University HospitalCopenhagenDenmark
  2. 2.The Finsen InstituteCopenhagenDenmark

Personalised recommendations